ArticleEuropean clinical respiratory journal2025
Results of frequent CT surveillance on recurrence detection and survival after radical resection for non-small cell lung cancer.
Article in European clinical respiratory journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Non-small lung cancer (NSCLC) carries a substantial risk for recurrence even after complete resection. Evidence regarding the survival impact of post-resection surveillance strategies remains limited. Danish guidelines for lung cancer recommend contrast-enhanced computed tomography (CE-CT) every 3 months for the first 2 years and every 6 months for the subsequent 3 years, a frequency twice that of major international guidelines. This study retrospectively assessed the outcomes of this high-frequency CT surveillance in Denmark, specifically focusing on recurrence detection within two years post-surgery, the potential for renewed curative-intent treatment, and post-recurrence prognosis during this initial period. Method: A cohort of 1079 patients who underwent resection for NSCLC in the period 2019-2020 was identified from the Danish Lung Cancer Registry (DLCR). Detailed information regarding new diagnoses of lung cancer, offered treatments, and mortality was extracted from patients' medical records. Results: Within two years following resection, 20% of patients developed a new diagnosis of lung cancer. Of these, 28.5% presented with localized disease (stage I-II), 26% with locally advanced disease (stage III), and 45% with metastatic disease. Recurrence frequencies ranged from 13% for pathological stage I (pStage I) to 44.5% for pStage III. Forty-eight percent of patients were offered renewed curative-intent treatment, demonstrating a 2-year post-recurrence survival of 78%. In contrast, patients offered palliative care or no treatment had a 2-year post-recurrence survival of 40%. Conclusion: The proportion of recurrences presenting with metastatic disease was lower than reported in cohort studies with less frequent surveillance. A further notable finding was the high proportion of patients offered curative-intent treatment for recurrent disease, exceeding previously reported rates. These patients demonstrated a 2 year post-recurrence survival comparable to that observed following a primary NSCLC diagnosis. The presence of symptoms at the time of recurrence was a negative prognostic indicator, even among patients receiving palliative treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.